Evidence map›Paper›PMID 42830620›Full record

ArticleNeuropathology and applied neurobiology2026

A Case of Primary Intramedullary Infantile Fibrosarcoma With an RBPMS::NTRK3 Fusion and Response to Larotrectinib.

Mégane Le Quang, Julie Tandonnet, Nathalène Truffaux, Lucile Vanhersecke, Jean Delmas, Arthur Durouchoux, Dorian Bochaton, Arnault Tauziède-Espariat, Guillaume Chotard

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropathology and applied neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mégane Le QuangDepartment of Pathology, University Hospital of Bordeaux, Bordeaux, France.ORCID https://orcid.org/0009-0009-4181-1014
Julie TandonnetPediatric Hematology and Oncology Unit, University Hospital of Bordeaux, Bordeaux, France.ORCID https://orcid.org/0009-0009-4037-4297
Nathalène TruffauxInstitut Bergonié, Department of Biopathology, Bordeaux, France.
Lucile VanherseckeInstitut Bergonié, Department of Biopathology, Bordeaux, France.ORCID https://orcid.org/0000-0001-7733-7806
Jean DelmasDepartment of Radiology, University Hospital of Bordeaux, Bordeaux, France.ORCID https://orcid.org/0000-0002-6847-4953
Arthur DurouchouxDepartment of Neurosurgery, University Hospital of Bordeaux, Bordeaux, France.
Dorian BochatonDepartment of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, Paris, France.ORCID https://orcid.org/0009-0006-5390-9500
Arnault Tauziède-EspariatDepartment of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, Paris, France.ORCID https://orcid.org/0000-0002-9979-0297
Guillaume ChotardDepartment of Pathology, University Hospital of Bordeaux, Bordeaux, France.ORCID https://orcid.org/0000-0003-0992-1597

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of primary intramedullary infantile fibrosarcoma (IFS) in a 4-week-old infant with rapidly progressive cervical myelopathy. Histology showed a spindle cell tumour with diffuse S100 and pan-TRK expression. RNA sequencing identified an RBPMS::NTRK3 fusion. RNA-based clustering and DNA methylation profiling classified the tumour as IFS. Treatment with the TRK inhibitor, larotrectinib, achieved marked clinical and radiological recovery within 1 month, expanding the spectrum of NTRK-rearranged sarcomas and confirming TRK inhibition's efficacy in primary central nervous system IFS.

Indexed as

FibrosarcomaPyrimidinesReceptor, trkCSpinal Cord NeoplasmsTriazolesHumansProtein Kinase InhibitorsPyrazoleslarotrectinibNTRK3 protein, humanProtein Kinase InhibitorsPyrazolesPyrimidinesReceptor, trkCTriazolescentral nervous system tumourinfantile fibrosarcomaintramedullary tumourlarotrectinibRBPMS::NTRK3 fusion

Identifiers

PMID42830620
PMCPMC13635763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.